Last reviewed · How we verify
A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
Details
| Lead sponsor | Asan Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 31 |
| Start date | 2010-07 |
| Completion | 2018-07 |
Conditions
- Advanced Gastric Cancer
Interventions
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Primary outcomes
- R0 resection rate — Up to 4 weeks after surgery
R0 resection means complete resection of tumor.
Countries
South Korea